Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Horvath, Dennis, Termperton, Nigel, Mayora-Neto, Martin, Da Costa, Kelly, Horlacher, Reinhold, Günther, Armin, Brosig, Alexander, Morath, Jenny, Jakobs, Barbara, Groettrup, Marcus, Hoschuetzky, Heinz, Rohayem, Jacques, ter Meulen, Jan,
Formato: Artículo
Lenguaje:inglés
Publicado: Philipps-Universität Marburg 2023
Materias:
Immunology
Medizin
Biotechnology
Microbiology
Medical sciences Medicine
Acceso en línea:Texto Completo PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

Texto Completo PDF

Detalle de Existencias desde
Número de Clasificación: urn:nbn:de:hebis:04-es2024-04361
Fecha de Publicación: 2024-01-17
Fuente: Erstveröffentlichung: Horvath, D., Temperton, N., Mayora-Neto, M. et al. Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice. Sci Rep 13, 4648 (2023). https://doi.org/10.1038/s41598-023-31198-3
Downloads: 9 (2024)
Lizenz: https://creativecommons.org/licenses/by/4.0
URL de Acceso: https://archiv.ub.uni-marburg.de/es/2024/0436
https://doi.org/10.1038/s41598-023-31198-3

Ejemplares similares